Latest Diabetes mellitus type 1 Stories

In Just 23 Days, Over 100,000 Individuals Sign Petition for the FDA to Advance, Not Delay, the Development of an Artificial Pancreas WASHINGTON, Nov. 2, 2011 /PRNewswire-USNewswire/ -- U.S. Senators, clinical experts, and people with type 1 diabetes (T1D) today urged the Food and Drug Administration (FDA) to issue clear and reasonable guidance on the artificial pancreas (AP) that avoids unnecessary delays in development and delivery of a medical technology and improves the lives of millions...

-- Two of the largest funders of type 1 diabetes research and development will collaborate in key priority areas to accelerate the pace of progress -- NEW YORK, Nov. 2, 2011 /PRNewswire-USNewswire/ -- JDRF and The Leona M. and Harry B. Helmsley Charitable Trust, two of the largest non-government funders of type 1 diabetes (T1D) programs, announced today that they have formalized a collaboration that will foster a new level of cooperation between the organizations. The goal of...

-- Children's Hospital of Philadelphia Researchers Use a Diabetes Drug to Permanently Reprogram Insulin-Producing Cells -- PHILADELPHIA, Nov. 2, 2011 /PRNewswire-USNewswire/ -- Pediatric researchers who tested newborn animals with an existing human drug used in adults with diabetes report that this drug, when given very early in life, prevents diabetes from developing in adult animals. If this finding can be repeated in humans, it may become a way to prevent at-risk infants from...

DRI's unique research philosophy and promising research progress give patients and families real hope for a cure HOLLYWOOD, Fla., Nov. 1, 2011 /PRNewswire-USNewswire/ -- Beginning today, the Diabetes Research Institute Foundation is giving those with diabetes and their loved ones continued hope for a cure with the launch of its "Reason to Believe" campaign. Kicking off National Diabetes Awareness Month, Reason to Believe, or r2b, will emphasize the organization's singular focus on curing...

LANSING, Ill., Nov. 1, 2011 /PRNewswire/ -- Land O'Frost, the nation's largest family-owned packaged lunch meat brand, today announced a multi-year partnership with JDRF, focused on raising much-needed funds for type 1 diabetes (T1D) research and creating awareness of the organization and their efforts to cure, treat, and prevent T1D. This partnership builds on an informal relationship Land O'Frost has had with JDRF since 2008. Over the past three years, Land O'Frost employees have rallied...

SAN DIEGO, Nov. 1, 2011 /PRNewswire/ -- Award-winning actor, dancer and singer Ben Vereen continues his efforts with Taking Control of Your Diabetes (TCOYD) with support from Sanofi US to encourage the nearly 26 million Americans living with diabetes to Start Taking Action Now for Diabetes (S.T.A.N.D.). The new public service announcement (PSA) features Ben and others living with diabetes who don't allow their condition to hold them back. To view the multimedia assets associated with this...

ALBANY, New York, November 1, 2011 /PRNewswire/ -- According to a new report published by Transparency Market Research ( http://www.transparencymarketresearch.com), "Global Diabetes Market: Drugs & Devices (2011 - 2016) [http://www.transparencymarketresearch.com/diabetes-devices-market.html ]"The global market for Diabetes Management accounted for USD 41.9 billion in 2010 and is expected to attain a market size of USD 114.3 billion in 2016 following a growth rate of 18.2%...

Viewers will learn about organization's singular focus on a cure and significant research progress HOLLYWOOD, Fla., Oct. 25, 2011 /PRNewswire-USNewswire/ -- As part of its 'Living with Diabetes' series airing through the end of the year, The Balancing Act on Lifetime Television is featuring the Diabetes Research Institute (DRI) in several segments to help educate viewers about diabetes and the progress being made toward a cure. The "Closing in on a Cure for Diabetes" segments begin airing...

MIAMI, Oct. 24, 2011 /PRNewswire/ -- In a study to be presented at the CTS-IXA Congress today, Lorenzo Piemonti, M.D., the director of the islet transplantation program at the San Raffaele Diabetes Research Institute of Milan, will show Phase II clinical data that supports the development of Reparixin for use in pancreatic islet transplantation experimental procedure as an alternative to pancreas transplant in patients with advanced stages of Type 1 diabetes who develop a resistance to...

OSAKA, Japan, Oct. 18, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc. ("TGRD U.S."), and Takeda Global Research & Development Centre (Europe), Ltd. ("TGRD Europe"), announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes. The program will be conducted across the United States (U.S.), Latin...